We confirmed the generalizability of the HF processes described by MCP1 and MCP2, with perfect classification of 12 tissue samples from HF patients across hypertrophic cardiomyopathy (HCM), ICM, and cardiac sarcoidosis etiologies, drawn from two studies without healthy reference patients (Fig. 6B). This evidence concerns the gene CCL2 and hypertrophic cardiomyopathy.